Moderna, Inc. (MRNA) Stock

About Moderna, Inc.

Moderna, Inc. is led by CEO Stéphane Bancel, employs 5,800 people, headquartered in Cambridge, US, publicly traded since 2018.

Moderna, Inc. (MRNA) stock trades at $197.00 with a market capitalization of $78.17B. The stock is valued at a price-to-earnings (P/E) ratio of -24.92, price-to-book of 11.65, price-to-sales of 35.42. Over the past 52 weeks the stock has ranged between $22.28 and $211.22, and currently trades 6.7% below its 52-week high.

On profitability, Moderna, Inc. generates a return on equity (ROE) of -39.20%, return on capital employed of -39.40%, an operating margin of -1.31%, a net profit margin of -141.43%.

In its most recent fiscal year, Moderna, Inc. reported annual revenue of $1.9B, net profit of $-2.8B, revenue has compounded at 19.3% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.19 — a conservative balance sheet with little leverage risk, a current ratio of 2.41, total assets of $12.3B, $2.6B in cash and equivalents.

MRNA has a beta of 0.90.